Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause.

Abstract

OBJECTIVE:

To assess the therapeutic value of treatment with an HMG-CoA reductase inhibitor in women with hypoestrogenic hyperlipidemia caused by menopause.

DESIGN:

Fifty-six women with total cholesterol (TC) levels of 220 mg/dl or more who were within 7 years of menopause were randomly assigned to receive an HMG-CoA reductase inhibitor (pravastatin 10 mg/day; treated group, 26 patients) or no medical treatment (nontreated group, 30 patients) in this 6-month nonblinded prospective trial.

RESULTS:

In the treated group, the mean (SD) TC levels decreased significantly from 254.5+/-22.3 mg/dl at baseline to 204.7+/-22.2 mg/dl (19.6%), and the mean low-density lipoprotein cholesterol (LDL-C) level decreased significantly from 146.7+/-30.5 to 104.3+/-22.5 mg/dl (28.9%); the mean arteriosclerotic index decreased significantly from 2.98 to 2.08 (30.2%). There were no significant changes in either triglyceride levels or high-density lipoprotein cholesterol (HDL-C) levels. In the nontreated group, there were no significant changes in the TC, HDL-C, LDL-C, or triglyceride levels; there was also no change in the arteriosclerotic index. After 6 months, the TC level, LDL-C level, and arteriosclerotic index were significantly lower in the treated group compared with the nontreated group (p<0.01).

CONCLUSIONS:

The results indicate that the HMG-CoA reductase inhibitor lowered TC and LDL-C levels and was useful in the treatment of hypoestrogenic hyperlipidemia for periods of at least 6 months.

• Authors: H Ohta, A Masuda, T Fuyuki, I Sugimoto, Y Suda, K Makita, K Takamatsu, F Horiguchi, S Nozawa
• Journal: Hormone research (Horm Res) Vol. 53 Issue 3 Pg. 120-4 ( 2000) ISSN: 0301-0163 [Print] Switzerland
• PMID: 11044791 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
• Copyright: Copyright 2000 S. Karger AG, Basel.

Chemical References

• Cholesterol, LDL
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Lipids
• Pravastatin

Topics

• Arteriosclerosis (blood)
• Cholesterol, LDL (blood)
• Female
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Hyperlipidemias (drug therapy)
• Japan
• Lipids (blood)
• Menopause (physiology)
• Middle Aged
• Pravastatin (therapeutic use)